In a report released on July 28, Anthony Petrone from Mizuho Securities reiterated a Buy rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $75.00. The ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Sacral neuromodulation may not work for everyone, but Axonics is hoping to more accurately identify those who may indeed be good candidates for the technology. The devicemaker has acquired a new ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target of $71.00. The company’s shares opened today at ...

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...

Axonics Modulation Technologies (AXNX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.The firm develops and commercializes minimally ...

As of March 24, 2023, the average one-year price target for Axonics Modulation Technologies is $84.09. The forecasts range from a low of $65.65 to a high of $94.50. The average price target represents ...

Weighted-average shares used to compute basic and diluted net loss per share ...